Expert Interview
Discussing the Approval of Insmed's Brinsupri in non cystic fibrosis bronchiectasis, as well as potential of Treprostinil Palmitil Inhalation Powder (TPIP) for the treatment of Pulmonary Arterial Hypertension (PAH)
Ticker(s): INSMInstitution: Sharp Medical Group
- Clinical Pulmonologist at Sharp Medical Group in San Diego, CA
- Manages 30+ patients with PAH and NCFBE
- Clinical and Research interest in PAH and Critical Care Medicines; Familiar with investigational agents in PAH/NCFBE
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
